Tirzepatide-Associated Colonic Ischemia.
David Bayless1, Jasraj Singh1, Byoung Uk Park1
1Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
ACG Case Reports Journal
|November 7, 2024
Summary
Tirzepatide, a GLP-1/GIP agonist used for weight loss and diabetes, may be linked to colonic ischemia. This case report suggests a potential risk and highlights factors to consider before prescribing this popular medication.
Area of Science:
- Endocrinology
- Gastroenterology
- Pharmacology
Background:
- Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, such as tirzepatide, are increasingly prescribed for weight loss and type 2 diabetes management.
- Common side effects include gastrointestinal issues like nausea, vomiting, and constipation.
Observation:
- A case of colonic ischemia was observed in a 62-year-old female patient undergoing tirzepatide treatment for weight loss.
- The ischemic event occurred during the course of tirzepatide therapy.
Findings:
- This case suggests a potential association between GLP-1/GIP agonist therapy and the development of colonic ischemia.
- The findings highlight the need to consider this rare but serious adverse event in patients using tirzepatide.
Implications:
- Healthcare providers should be aware of the potential risk of colonic ischemia with tirzepatide use.
- Identifying and managing risk factors is crucial for patient safety when prescribing GLP-1/GIP agonists.
More Related Videos
07:12Targeting the Rat's Small Bowel: Long-Term Infusion into the Superior Mesenteric Artery
Published on: April 8, 2021
4.2K
05:32Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection
Published on: September 21, 2015
32.1K
Related Concept Videos
01:17Drugs for Treatment of Diarrhea-Predominant IBS
149
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
149
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
212
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
212
01:21Drugs for Treatment of Constipation-Predominant IBS
137
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
137
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
145
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
145
01:29Drugs for Treatment of Ulcerative Colitis in IBD
124
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
124
01:30Inflammatory Bowel Disease II: Crohn's Disease
188
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
188